Tresiba® demonstrated significantly lower rates of overall, nocturnal and severe hypoglycaemia vs insulin glargine U-100
New Orleans, US, 11 June 2016 – New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba® (insulin...







